ReoPro (Centocor)

ReoPro (Centocor) - General Information

Fab fragment of the chimeric human-murine monoclonal antibody 7E3. ReoPro (Centocor) binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation.

Pharmacology of ReoPro (Centocor)

Used for the treatment of myocardial infarction and the prevention of platelet aggregation. ReoPro (Centocor) inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets.

ReoPro (Centocor) for patients

ReoPro (Centocor) Interactions

Formal drug interaction studies with Abciximab have not been conducted. Abciximab has been administered to patients with ischemic heart disease treated concomitantly with a broad range of medications used in the treatment of angina myocardial infarction and hypertension. These medications have included heparin warfarin, beta-adrenergic receptor blockers, calcium channel antagonists, angiotensin converting enzyme inhibitors, intravenous and oral nitrates, ticlopidine, and aspirin. Heparin, other anticoagulants, thrombolytics, and anti platelet agents are associated with an increase in bleeding. Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.

ReoPro (Centocor) Contraindications

Because Abciximab may increase the risk of bleeding, Abciximab is contraindicated in the following clinical situations:

� Active internal bleeding

� Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance.

� History of cerebrovascular accident (CV A) within two years, or CV A with a significant residual neurological deficit

� Bleeding diathesis

� Administration of oral anticoagulants within seven days unless prothrombin time is <1.2 times control

� Thrombocytopenia (<100 000 cells/m L)

� Recent (within six weeks) major surgery or trauma

� Intracranial neoplasm, arteriovenous malformation, or aneurysm

� Severe uncontrolled hypertension

� Presumed or documented history of vasculitis

� Use of intravenous dextran before PC I, or intent to use it during an intervention Abciximab is also contraindicated in patients with known hypersensitivity to any component of this product or to murine proteins.

Additional information about ReoPro (Centocor)

ReoPro (Centocor) Indication: For treatment of myocardial infarction, adjunct to percutaneous coronory intervention, unstable angina
Mechanism Of Action: ReoPro (Centocor) binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPlIb/IIIa.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Abciximab
Synonyms: 7E3 antibody; ReoPro; antiGPIIBIIIa
Drug Category: Anticoagulants; Antiplatelet Agents
Drug Type: Biotech; Approved

Other Brand Names containing Abciximab: ReoPro (Centocor);
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Most likely removed by opsonization via the reticuloendothelial system when bound to platelets, or by human antimurine antibody production
Half Life: 10-30 min
Dosage Forms of ReoPro (Centocor): Solution Intravenous
Chemical IUPAC Name: Chimeric human-murine (anti CD41) 7E3 antibody.
Chemical Formula: C6462H9964N1690O2049S48
Abciximab on Wikipedia: https://en.wikipedia.org/wiki/Abciximab
Organisms Affected: Humans and other mammals